Advisory Research Inc Intra Cellular Therapies, Inc. Transaction History

Advisory Research Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$52.09 - $64.1 $177,731 - $218,709	3,412 Added 15.56%	25,333 $1.32 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $957,545 - $1.16 Million	17,515 Added 397.53%	21,921 $1.39 Million
Q1 2023 May 12, 2023	BUY	$43.8 - $56.99 $192,982 - $251,097	4,406 New	4,406 $238,000
Q2 2022 Aug 17, 2022	SELL	$43.0 - $65.64 $178,063 - $271,815	-4,141 Reduced 10.21%	36,414 $2.08 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $288,651 - $462,632	7,451 Added 22.51%	40,555 $2.48 Million
Q4 2021 Feb 11, 2022	BUY	$35.2 - $53.42 $885,808 - $1.34 Million	25,165 Added 316.98%	33,104 $1.73 Million
Q3 2021 Nov 12, 2021	BUY	$28.72 - $42.49 $228,008 - $337,328	7,939 New	7,939 $296,000

381

84M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.